Nascent Biotech, Inc.

OTC:NBIO

0.23 (USD) • At close November 27, 2023
Bedrijfsnaam Nascent Biotech, Inc.
Symbool NBIO
Munteenheid USD
Prijs 0.2
Beurswaarde 29,927,398
Dividendpercentage 0%
52-weken bereik 0.032 - 0.43
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sean Carrick
Website https://www.nascentbiotech.com

An error occurred while fetching data.

Over Nascent Biotech, Inc.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.

Vergelijkbare Aandelen

CareView Communications, Inc. logo

CareView Communications, Inc.

CRVW

0.061 USD

Fuse Medical, Inc. logo

Fuse Medical, Inc.

FZMD

0.166 USD

DATATRAK International, Inc. logo

DATATRAK International, Inc.

DTRK

0.51 USD

iAnthus Capital Holdings, Inc. logo

iAnthus Capital Holdings, Inc.

ITHUF

0.03 USD

iCoreConnect Inc. logo

iCoreConnect Inc.

ICCT

0.001 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)